title: VEGF-A and FGF gene therapy accelerate healing of ischemic colonic anastomoses (experimental study).
abstract: BACKGROUND
  Reducing ischemic damage is one of the goals of surgery. The aim of this study was to apply human VEGF-A and FGF-2 DNA-mediated gene therapy in order to identify their effects in the healing of ischemic colon anastomoses and eliminating the negative effects of ischemia.
  
  
  METHODS
  Forty male Wistar albino rats weighing 250-280 g were divided into five equal groups (n = 8) as follows: group 1: control, ischemic left colonic anastomosis; group; 2: ischemic left colonic anastomosis with control plasmid delivery; group 3: ischemic left colonic anastomosis with VEGF plasmid delivery; group 4: ischemic left colonic anastomosis with FGF plasmid delivery; group 5: ischemic left colonic anastomosis with VEGF and FGF plasmid delivery. All rats were sacrificed on the 4th postoperative day. Anastomosis burst pressures were measured for mechanical examination of anastomosis. Tissue hydroxyprolin, VEGF and FGF levels were determined as biochemical parameters. Necrosis, epithelisation, inflammatory processes, fibroblastic activity, collagen deposition and neovascularisation at the anastomic site were studied.
  
  
  RESULTS
  VEGF, FGF and combined therapy significantly accelerated many of the histological parameters of healing, including fibroblast activation, collagen deposition, and angiogenesis, and augmented the levels of hydroxyproline and bursting pressure.
  
  
  CONCLUSIONS
  This is the first study to use gene therapy with growth factors for the healing of ischemic colonic anastomosis. This therapy can be effectively used in increasing ischemic anastomosis wound healing.
authors.affiliation: Okmeydani Education and Research Hospital, Department of Surgery, Turkey.
authors.forename: Gokhan
authors.initials: G
authors.lastname: Adas
authors.forename: Askın
authors.initials: A
authors.lastname: Percem
authors.forename: Mine
authors.initials: M
authors.lastname: Adas
authors.forename: Ozgur
authors.initials: O
authors.lastname: Kemik
authors.forename: Soykan
authors.initials: S
authors.lastname: Arikan
authors.forename: Duran
authors.initials: D
authors.lastname: Ustek
authors.forename: Aris
authors.initials: A
authors.lastname: Cakiris
authors.forename: Neslihan
authors.initials: N
authors.lastname: Abaci
authors.forename: Ahu Sarbay
authors.initials: AS
authors.lastname: Kemik
authors.forename: Gulcin
authors.initials: G
authors.lastname: Kamali
authors.forename: Servet
authors.initials: S
authors.lastname: Karahan
authors.forename: Adem
authors.initials: A
authors.lastname: Akcakaya
authors.forename: Oguzhan
authors.initials: O
authors.lastname: Karatepe
mesh_terms: D000714:Anastomosis, Surgical; D000818:Animals; D003106:Colon / Q000098:blood supply* / Q000601:surgery*; D004195:Disease Models, Animal; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D005500:Follow-Up Studies; D007511:Ischemia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008297:Male; D011183:Postoperative Complications; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D042461:Vascular Endothelial Growth Factor A; D005346:Fibroblast Growth Factors